Frank, us for all and to thanks morning. you, you Thank joining this of
quarter PDSXXXX, there trials. our related clinical with targets our with study the trials. progress National ongoing at oncology Starting HPVXX XXXX associated cancers, clinical lead at most I'll incredible II made data HPV are the Institute candidate which have ASCO this we in was our detailed, cancers. in study presented Cancer pipeline is progress The first Phase ongoing being with June oncology a our just begin Interim Frank advanced three call. As since performed for meeting.
the cytokine facilitate of designed MXXXX, by with checkpoint for human Bintrafusp trials functional As as Frank conjugated MXXXX, tumors. initiated clinical PDSXXXX an proof-of-concept of the investigator first in technology into advanced for mentioned, entry alfa represents I'll overview the a cancer with study class known platform. antibody these data designed PDSXXXX to combination a Versamune inhibitor and clinical of in begin in an first our cytokine this data ILXX
Moving Most as returned forward, this study evaluate are with to set. NCI associated in cases I'll both From associated refer those inhibitor refractory caused the to than cancers, Bintrafusp designed to checkpoint The these are of and that cancers alfa or in we treatment. after with that epidemiology HPV progressed HPV have HPVXX by Bintraf. treatment represented XX% greater is advanced know XX% cancers naive associated infection. reports, U.S combination of XX% all data patients
As response Today response autogenic These responses having Frank vulvar patients. trial is similar to patients the include by the demographic head often radiation to the inhibitor X.X. both of in according cancer. see challenging XX% an the also Institute approximately we'll to data can review and half that the vaginal includes RECIST and Maryland as presented failed ORR, treatment, evaluate XX study vaginal other the the objective neck come treat. standard interim and of also The to patients, vulvar and be tumor Of trial, the and rate objective XX noted, followed or to this dataset, anal, had difficult have is study. options, cancers. The XX patient study rate type. tumor cervical In that chemotherapy with radiographic therapy. neck, ultimately had of anal, checkpoint that National in composition date will data. patients exhausted overall population, by most Cancer majority cervical, in they measured reflected XX% all to treatment we included cancer, known types and failed cancers high-risk of head HPV the look to seen in a The at care and enrolled in a Bethesda, evaluated the total accrued population and these patients Patients the in when
HPVXX XX was XX were and XX X Importantly, about XX follow-up The HPVXX of HPVXX and refractory. inhibitor naive, positives, patients, Of checkpoint were were months. were positive checkpoint X negative. inhibitor median patients, represented X the study
or pretreated. positive objective patients. of reported difficult Again, Let's of have inhibitor already begin response rate. patients RECIST outstanding complete of cancer the to these expectation achieved objective reduction population, checkpoint is to previously as around who therapy this are so an in This XX% objective burden by prior The had checkpoint who generally and triple date heavily response an Of response. received X.X because combination treat, achieved X defined population standard X rates failed a And tumor the patient is XX% exceeds they patients result very with inhibitors, is more. objective the far is this checkpoint HPVXX as patient thus to response not advanced inhibitors naive HPV a XX% with XX%. at X had care in responses least
also this triple durability HPVXX positive Importantly, checkpoint shows patients. in inhibitor these promising combination
have halting came and the off response. are median As alive. an patient One patients the months XX% Xight of patients these follow-up combination all ongoing response X of at of a
attacking standard care tumor vivo, months suggest also For the PDSXXXX in effective CDX checkpoint interim studies a HPVXX result preclinical context, of that inhibitor in X preliminary survival humans. this T-cells results patient in highly to mean in with active These population historical animal of tumor has tumor documented XX therapy. in of published shrinkage adoption may
radiation additional chemotherapy, patients initial patients in These patients. the Moving of the objective XX% dataset, population, checkpoint had yet HPVXX the as the the who tumor but criteria included had XX XX% reduction this inhibitor X were positive X inhibitors. patients failed this or the greater met time X patients now are X These In X, treatment of triple combination ongoing in have treated response. for as in threshold at a well achieved therapy the reporting, refractory already XX Of had in to of checkpoint not patients abstract, or with tumor reported XX% arm. patients reduction updated reduction. tumor
As XX expected the are to patients standard checkpoint generally objective refractory rates only HPVXX these positive similar the to reported a patients of ongoing XX% HPV checkpoint inhibitors, responses patients. combination durability XX%. XX% X reduction. refractory care, patients even Encouragingly, objective checkpoint naive of That also be than also showed promising had these inhibitor of had alive importantly, patients checkpoint lower in cancer tumor XX XX% might advanced response X patients, with ongoing the at in who triple response those an X% months. XX, have achieved months of And are had median a median notable. of of of is potential
As limited extensively again less unlikely effective historical for responses. X checkpoint in PDSXXXX attacking refractory only CDX induction even population HPVXX X median that, in durable tumor months. potential disease than immunologically These survival patient preliminary half has treated and killer generally of results of present reduction patients suggest T-cells, highly this to a active strong vivo unprecedented
As with other relative a arises results that seen components question contribution triple combination in the individual the is so combination far. of common regimen, any to encouraging the
negative his data benefit? therapies question in are PDSXXXX the Dr. to three Strauss posed The helps role was, ASCO the HPVXX on presentation to believe you elucidate clinical the do of triple combination. top the following all Specifically, patients contributing
HPV the are the cervical, vaginal the it very not in is, well as is clinical and that are where enrollment. the equally are survival cancers. as exclusively suggests in a leverages understand These alive to patients related to includes particularly expressing agnostic the naive that experienced document they immunotherapeutic inhibitor encouraging XX% for patients Furthermore, and XX% on exposure. in advanced You'll is of in it refractory HPVXX, in that with study, at specificity HPV Versamune, is types of the body survival the targeted molecularly tumors of that HPVXX antigens, positive a tumor HPVXX of the preclinical checkpoint of as positive important enhance impressive heavily This cancer X these zero follow-up. attack well Versamune patients at patients and It's CDX X to In important recall PDSXXXX and other This HPVXX CDX still HPV cancer expresses matter recognize. qualify of system EX. and which with that do and this cancers, treatment. immune strong T-cell anal, of vulvar induced median HPVXX what negative strain tumor that the studies, checkpoint case, as months the is promoting of promote also EX negative immune molecular antigen patients reduction of is treatment alive. head months. conducted alive as T-cells responses has patients which triple patients preliminary trial train required specifically also and of by it this target of actually T-cell X those negative PDSXXXX, to PDSXXXX being the system and in induction combination. definitively HPVXX Among than the were patients, triple only in observations that tumor X of of inhibitor neck, majority implications this reduction regardless with tumor of remarkably, XX% in as effective data responses all the the prior are suggest target express the These elimination the treated the of not potential the combination contrast, patients, experienced In median a as metastatic tumor these seen advanced PDSXXXX HPVXX critical type combined long even so X tumor HPVXX disease. by reduction. benefit for of specific with clinical patients may in HPVXX a patients may an role positive CDX because suggest also Results predicted in of
data for with the activity. treatment the toxicity or associated limited with important additional combination anti-tumor regimen associated consideration safety Turning avoid trial. excess now to A very to oncology is
with observed date combination to triple of monotherapy consistent not with Importantly, previously a a adverse those appear The MXXXX toxicities PDSXXXX triple does and Bintraf to documented treatment. therapy. with compile combination are events
occurred X hematuria, in most treatment-related The to events of gross Specifically, due approximately adverse of known events lymphocytes patients. anemia Grade XX% like TRAEs, also were as treatment-related decreased adverse frequent symptoms. the presence flu and
forward of efficacy each the safety the clinical micrograms expected in We be both the who combination. were addition from of that very equal the delivered patients kilogram data micrograms the with safety the data or as subcutaneously, by MXXXX XX.X than at Grade, note XX% being no contribution worsening combination questions as greater to as dose site to addition X as MT evaluation would lowered as important of we observed including of triple the the these the the to dose -- triple was to the reactions understand the and or toxicities to tolerated as patients well were answer to individual to toxicities well with Grade per seen Again, had Grade new As regarding from combination, combination, when well look of originally X toxicities. these set as per profile of important the outcomes. patients XX% kilogram to of patients. X to PDSXXXX MXXXX. of any further MXXXX continued more X seek it's injection components PDSXXXX the without
onto Now the study. sponsored PDS VERSATILE-XXX
just combination enrollment. progress, preliminary result as also include sites VERSATILE-XXX in have during patients refractory continues The of activation inhibitor checkpoint remarks, sites trial NCI-led population to Frank his of and a open currently the results to VERSATILE-XXX we to this study enrollment recently discussed in observed and talked I As expanded impressive XX triple about. in the was
of study North the the efficacy available will We serves months Head on patients in the in X leading in Medicine, and Center. to Cancer is essentially checkpoint of initial data naive treatment revised arms. of Thoracic principal XX unchanged design, QX assess XXXX, refractory and cohort the XXXX. assessed of late of Dr. Care of subjects School patient preliminary with The Chief number objective who as the the months the University or coming safety part and estimate safety Lineberger There of be XX both Carolina Neck Jared a data after the Weiss, at and be design. of of revised As total QX is responses lead the patients investigator Comprehensive is Section anticipate two-stage of [indiscernible] at to XX Oncology combination and
to thrilled important this Weiss involved in have study. are We Dr.
with therapies, KEYTRUDA patients medical to the including and an there We potential options. head is who PDSXXXX limited combination similarly and who of believe trial, NCI-led advanced enormous these chemotherapy, unmet have multiple significantly As failed have need neck cancer treatment for inhibitor clinical in improved has and therapy. checkpoint the patients outcomes the radiation
cancer. patients trial outcomes. study enroll now standard the Phase XX approximately will cervical known of preliminary Anderson MD to also care, It This combination effect in the led PDSXXXX clinical and the locally on the advanced oncologic for Moving investigate II of is chemoradiotherapy of as treatment combination with of safety IMMUNOCERV. and
We both to cancer. and believe Importantly, and blood is system priming immune to cervical immune tumor patients study immune targeting provide with T-cells tumor activate PDSXXXX the outcomes response may biomarkers tissue. in also ability exploring the by various improved induce the killer PDSXXXX of demonstrated by studying
readout of Cancer Dr. Oncology the being XXXX. Klopp, is Ann Professor second of first Associate the Radiation conducted Anderson The anticipated clinical of is M.D., The by Ph.D., from study at study Center. data MD this during half
and been by the ongoing Frank site single study, has heavily COVID mentioned, As impacted pandemic. a it this is
will at ongoing continue work the excellent We team monitor closely to MD Anderson with recruitment. to
is for Frank ongoing infectious programs. noted, our As work also disease
and preclinical progressing has of call. PDSXXXX update time work program, a earnings preclinical flu by steadily, the I studies next universal those detailed more have our our been to on For hope
approval the Farmacore. PDSXXXX, initiated cannot partner Brazil ANVISA our in I/II be to study provides Phase For clinical until planned
review Seth? would a program Voorhees, conducting the determine full be Van like quarter XXXX to with Seth Farmacore second turn Officer, the I review forward. over appropriate path our now Financial to to will our Chief We to call financials.
